<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01227187</url>
  </required_header>
  <id_info>
    <org_study_id>F1K-MC-1003</org_study_id>
    <nct_id>NCT01227187</nct_id>
  </id_info>
  <brief_title>Safety and Dose Finding Study of Xigris in Hemodialysis Patients</brief_title>
  <acronym>Xigris1003</acronym>
  <official_title>Safety and Dose Finding Study of Xigris (Drotrecogin Alfa Activated) as an Anti-coagulant in End Stage Renal Disease (ESRD) Patients Treated With Hemodialysis (HD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>George Washington University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>George Washington University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the safety of Xigris (Drotrecogin alfa) as an
      anticoagulant at different dose levels during dialysis treatment in patients with End Stage
      Renal Disease (ESRD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In United States, there are over 300,000 patients with ESRD who require hemodialysis.
      Clinical hemodialysis takes place three times a week and is dependent on adequate
      anticoagulation throughout the three to four hour procedure. Infection is one of the most
      common causes of death for patients with ESRD treated with hemodialysis (25%).

      Xigris (drotrecogin alfa activated) is a recombinant form of human activated protein C and is
      successfully used for treatment of adult patients with severe sepsis. In addition to its
      fibrinolytic properties, drotrecogin alpha has both an anti-inflammatory effect, and an
      anti-coagulant effect. However, there are few safety and no efficacy data on the effect of
      Xigris in ESRD patients as an anticoagulant.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the level of Partial Thromboplastin Time (PTT).</measure>
    <time_frame>PTT level at 15 minutes after start up of Xigris during the hemodialysis treatment.</time_frame>
    <description>PTT level during a hemodialysis treatment will be used to assess the effectiveness of Xigris as an anticoagulant. The goal of the study is to maintain the PTT level between 65-100 seconds during the treatment. If PTT is &lt;60 or &gt;100, the dose will be adjusted by 6 mcg/kg/h in the consecutive patient to a minimum dose of 12 mcg/kg/h or up to a maximum dose of 36 mcg/kg/h.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the level of Partial Thromboplastin Time (PTT).</measure>
    <time_frame>PTT level at 30 minutes after start up of Xigris during the hemodialysis treatment</time_frame>
    <description>PTT level during a hemodialysis treatment will be used to assess the effectiveness of Xigris as an anticoagulant. The goal of the study is to maintain the PTT level between 65-100 seconds during the treatment. If PTT is &lt;60 or &gt;100, the dose will be adjusted by 6 mcg/kg/h in the consecutive patient to a minimum dose of 12 mcg/kg/h or up to a maximum dose of 36 mcg/kg/h.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the level of Partial Thromboplastin Time (PTT).</measure>
    <time_frame>PTT level at 60 minutes after start up of Xigris during the hemodialysis treatment.</time_frame>
    <description>PTT level during a hemodialysis treatment will be used to assess the effectiveness of Xigris as an anticoagulant. The goal of the study is to maintain the PTT level between 65-100 seconds during the treatment. If PTT is &lt;60 or &gt;100, the dose will be adjusted by 6 mcg/kg/h in the consecutive patient to a minimum dose of 12 mcg/kg/h or up to a maximum dose of 36 mcg/kg/h.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the level of Partial Thromboplastin Time (PTT).</measure>
    <time_frame>PTT level at 120 minutes after start up of Xigris during the hemodialysis treatment.</time_frame>
    <description>PTT level during a hemodialysis treatment will be used to assess the effectiveness of Xigris as an anticoagulant. The goal of the study is to maintain the PTT level between 65-100 seconds during the treatment. If PTT is &lt;60 or &gt;100, the dose will be adjusted by 6 mcg/kg/h in the consecutive patient to a minimum dose of 12 mcg/kg/h or up to a maximum dose of 36 mcg/kg/h.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the level of Partial Thromboplastin Time (PTT).</measure>
    <time_frame>PTT level at 180 minutes after start up of Xigris during the hemodialysis treatment.</time_frame>
    <description>PTT level during a hemodialysis treatment will be used to assess the effectiveness of Xigris as an anticoagulant. The goal of the study is to maintain the PTT level between 65-100 seconds during the treatment. If PTT is &lt;60 or &gt;100, the dose will be adjusted by 6 mcg/kg/h in the consecutive patient to a minimum dose of 12 mcg/kg/h or up to a maximum dose of 36 mcg/kg/h.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>Xigris</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Xigris used as anticoagulant in patients treated with hemodialysis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drotrecogin alfa activated</intervention_name>
    <description>We plan to determine the optimal dose of Xigris needed to achieve PTT between 65 and 100 secs. The study will test different dose regimens of Xigris. The initial patients will receive Xigris dosed at an infusion rate of 12 mcg/kg/h via the pre-filter arterial drip chamber via a standard intravenous pump. The PTT will be assessed from blood samples drawn at baseline,15,30,60,120 and 180 mins. The dose of Xigris will be adjusted in the following patients if the afferent PTT rises above 100 secs (normal range 25-40 secs) or if PTT remains &lt;65 secs. If PTT remains less than 65 secs, the dose will be increased to the second dose regiment of 18 mcg/kg/hr. The dose escalation will continue in increments of 6 mcg/kg/h to a maximum dose of 36 mcg/kg/h. Each patient will receive Xigris only once.</description>
    <arm_group_label>Xigris</arm_group_label>
    <other_name>Drotrecogin alfa (activated)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. &gt;18

          2. Usually used heparin with HD

        Exclusion Criteria:

          1. Plt &lt;100

          2. Pregnancy

          3. H/o bleeding diathesis

          4. H/o CVA

          5. Pt on Ticlid/plavix/warfarin

          6. SBP &gt;200

          7. BASELINE PTT&gt;50

          8. INR&gt;1.6
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lakhmir S Chawla, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>George Washington University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The George Washington University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hakim RM, Held PJ, Stannard DC, Wolfe RA, Port FK, Daugirdas JT, Agodoa L. Effect of the dialysis membrane on mortality of chronic hemodialysis patients. Kidney Int. 1996 Aug;50(2):566-70.</citation>
    <PMID>8840287</PMID>
  </reference>
  <reference>
    <citation>Hakim RM, Breyer J, Ismail N, Schulman G. Effects of dose of dialysis on morbidity and mortality. Am J Kidney Dis. 1994 May;23(5):661-9.</citation>
    <PMID>8172208</PMID>
  </reference>
  <reference>
    <citation>Held PJ, Port FK, Webb RL, Wolfe RA, Bloembergen WE, Turenne MN, Holzman E, Ojo AO, Young EW, Mauger EA, et al. Excerpts from United States Renal Data System 1995 Annual Data Report. Am J Kidney Dis. 1995 Oct;26(4 Suppl 2):S1-186.</citation>
    <PMID>7573030</PMID>
  </reference>
  <reference>
    <citation>Held PJ, Port FK, Wolfe RA, Stannard DC, Carroll CE, Daugirdas JT, Bloembergen WE, Greer JW, Hakim RM. The dose of hemodialysis and patient mortality. Kidney Int. 1996 Aug;50(2):550-6.</citation>
    <PMID>8840285</PMID>
  </reference>
  <reference>
    <citation>Kimmel PL, Peterson RA, Weihs KL, Simmens SJ, Alleyne S, Cruz I, Veis JH. Psychosocial factors, behavioral compliance and survival in urban hemodialysis patients. Kidney Int. 1998 Jul;54(1):245-54.</citation>
    <PMID>9648085</PMID>
  </reference>
  <reference>
    <citation>Lowrie EG, Laird NM, Parker TF, Sargent JA. Effect of the hemodialysis prescription of patient morbidity: report from the National Cooperative Dialysis Study. N Engl J Med. 1981 Nov 12;305(20):1176-81.</citation>
    <PMID>7027040</PMID>
  </reference>
  <reference>
    <citation>Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis. 1990 May;15(5):458-82.</citation>
    <PMID>2333868</PMID>
  </reference>
  <reference>
    <citation>Owen WF Jr, Lew NL, Liu Y, Lowrie EG, Lazarus JM. The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med. 1993 Sep 30;329(14):1001-6.</citation>
    <PMID>8366899</PMID>
  </reference>
  <reference>
    <citation>Causes of death. USRDS. United States Renal Data System. Am J Kidney Dis. 1997 Aug;30(2 Suppl 1):S107-17.</citation>
    <PMID>9259696</PMID>
  </reference>
  <reference>
    <citation>Kimmel PL, Phillips TM, Simmens SJ, Peterson RA, Weihs KL, Alleyne S, Cruz I, Yanovski JA, Veis JH. Immunologic function and survival in hemodialysis patients. Kidney Int. 1998 Jul;54(1):236-44.</citation>
    <PMID>9648084</PMID>
  </reference>
  <reference>
    <citation>Yeun JY, Levine RA, Mantadilok V, Kaysen GA. C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis. 2000 Mar;35(3):469-76.</citation>
    <PMID>10692273</PMID>
  </reference>
  <reference>
    <citation>Kaysen GA. Biological basis of hypoalbuminemia in ESRD. J Am Soc Nephrol. 1998 Dec;9(12):2368-76. Review.</citation>
    <PMID>9848794</PMID>
  </reference>
  <reference>
    <citation>Patient mortality and survival. USRDS. United State Renal Data System. Am J Kidney Dis. 1997 Aug;30(2 Suppl 1):S86-106.</citation>
    <PMID>9259695</PMID>
  </reference>
  <reference>
    <citation>Kaysen GA. Role of inflammation and its treatment in ESRD patients. Blood Purif. 2002;20(1):70-80. Review.</citation>
    <PMID>11803162</PMID>
  </reference>
  <reference>
    <citation>Bologa RM, Levine DM, Parker TS, Cheigh JS, Serur D, Stenzel KH, Rubin AL. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis. 1998 Jul;32(1):107-14.</citation>
    <PMID>9669431</PMID>
  </reference>
  <reference>
    <citation>Kaysen GA. C-reactive protein: a story half told. Semin Dial. 2000 May-Jun;13(3):143-6.</citation>
    <PMID>10833771</PMID>
  </reference>
  <reference>
    <citation>Owen WF, Lowrie EG. C-reactive protein as an outcome predictor for maintenance hemodialysis patients. Kidney Int. 1998 Aug;54(2):627-36.</citation>
    <PMID>9690231</PMID>
  </reference>
  <reference>
    <citation>Bleyer AJ, Russell GB, Satko SG. Sudden and cardiac death rates in hemodialysis patients. Kidney Int. 1999 Apr;55(4):1553-9.</citation>
    <PMID>10201022</PMID>
  </reference>
  <reference>
    <citation>Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr; Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001 Mar 8;344(10):699-709.</citation>
    <PMID>11236773</PMID>
  </reference>
  <reference>
    <citation>Bernard GR, Ely EW, Wright TJ, Fraiz J, Stasek JE Jr, Russell JA, Mayers I, Rosenfeld BA, Morris PE, Yan SB, Helterbrand JD. Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. Crit Care Med. 2001 Nov;29(11):2051-9.</citation>
    <PMID>11700394</PMID>
  </reference>
  <reference>
    <citation>Bernard GR, Macias WL, Joyce DE, Williams MD, Bailey J, Vincent JL. Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis. Crit Care. 2003 Apr;7(2):155-63. Epub 2003 Feb 28. Review.</citation>
    <PMID>12720562</PMID>
  </reference>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 14, 2010</study_first_submitted>
  <study_first_submitted_qc>October 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2010</study_first_posted>
  <last_update_submitted>July 20, 2012</last_update_submitted>
  <last_update_submitted_qc>July 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>George Washington University</investigator_affiliation>
    <investigator_full_name>Lakhmir Chawla</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Hemodialysis</keyword>
  <keyword>Anticoagulation</keyword>
  <keyword>Xigris</keyword>
  <keyword>PTT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Drotrecogin alfa activated</mesh_term>
    <mesh_term>Protein C</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>February 18, 2014</submitted>
    <returned>April 1, 2014</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

